<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04419090</url>
  </required_header>
  <id_info>
    <org_study_id>2020-01271</org_study_id>
    <nct_id>NCT04419090</nct_id>
  </id_info>
  <brief_title>Cascade Genetic Testing of Familial Hypercholesterolemia</brief_title>
  <acronym>CATCH</acronym>
  <official_title>Cascade Genetic Testing of Familial Hypercholesterolemia: the CATCH Multicenter Randomized Controlled Trial</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Center for Primary Care and Public Health (Unisante), University of Lausanne, Switzerland</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Swiss Athersclerosis Association</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Center for Primary Care and Public Health (Unisante), University of Lausanne, Switzerland</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Familial hypercholesterolemia (FH) is a frequent genetic disorder (1/200) associated with an
      increased risk of early-onset myocardial infarction. To improve detection and treatment of
      patient with FH, cascade genetic testing in families is recommended by many cardiovascular
      prevention guidelines. However, the implementation of national genetic cascade screening is
      challenging, because legal protection to guarantee privacy of data do not authorize
      physicians to directly contact at-risk relatives. Using current mobile information
      technologies and a centralized web-based platform, we designed an ethical genetic cascade
      screening program for FH to be tested in Switzerland.
    </textblock>
  </brief_summary>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">July 2020</start_date>
  <completion_date type="Anticipated">September 2022</completion_date>
  <primary_completion_date type="Anticipated">February 2022</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Factorial Assignment</intervention_model>
    <primary_purpose>Screening</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>the yield of detection of familial hypercholesterolemia (FH)</measure>
    <time_frame>2 years</time_frame>
    <description>The yield of detection is the number of test performed/number of contactable relatives.</description>
  </primary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Anticipated">400</enrollment>
  <condition>Familial Hypercholesterolemia</condition>
  <arm_group>
    <arm_group_label>Monogenic positive FH, direct contact</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Monogenic positive FH, usual care</arm_group_label>
    <arm_group_type>No Intervention</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Monogenic negative FH, direct contact</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Monogenic negative FH, usual care</arm_group_label>
    <arm_group_type>No Intervention</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>web-based centralized service and message</intervention_name>
    <description>Perform three cycles of cascade screening through several generation of family members of an index case. The contact of relatives will be initiated by the index case and supported by a web-based centralized service. The index case will be provided with a prepared email or Whatsapp message that the index case can further forward to his first-degree relatives. The email/message will contain a link to a secured web application with a code for the connection. By clicking on the link, the relative will connect to a specifically designed app. The app will provide information about the transmission mode of FH, the cardiovascular risk associated with FH and the way how to reduce this risk. The relative can then fill out information and provide agreement to be contacted for the study. The nearest specialized clinic will then contact the relative to organize further screening with similar processes.</description>
    <arm_group_label>Monogenic negative FH, direct contact</arm_group_label>
    <arm_group_label>Monogenic positive FH, direct contact</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  patients with severe hypercholesterolemia and familial or personal history of
             early-onset cardiovascular disease = Dutch Lipid Clinic Network score (DLNC) &gt;= 6
             points.

        Exclusion Criteria:

          -  Patients without at least one contactable first-degree family members
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>5 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>David Nanchen, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Center for Primary Care and Public Health (Unisante), University of Lausanne, Switzerland</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>David Nanchen, MD</last_name>
    <phone>+41213146107</phone>
    <email>david.nanchen@unisante.ch</email>
  </overall_contact>
  <verification_date>May 2020</verification_date>
  <study_first_submitted>June 3, 2020</study_first_submitted>
  <study_first_submitted_qc>June 3, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">June 5, 2020</study_first_posted>
  <last_update_submitted>June 3, 2020</last_update_submitted>
  <last_update_submitted_qc>June 3, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">June 5, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hyperlipoproteinemia Type II</mesh_term>
    <mesh_term>Hypercholesterolemia</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

